Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LGALS8 | O00214 | 1/20 | 0.46 |
| ▸ | LGALS3 | P17931 | 1/20 | 0.46 |
| ▸ | LGALS4 | P56470 | 1/20 | 0.46 |
| ▸ | ACHE | P22303 | 1/20 | 0.46 |
| ▸ | MAOB | P27338 | 1/20 | 0.45 |
| ▸ | SLC5A1 | P13866 | 1/20 | 0.45 |
| ▸ | SLC5A2 | P31639 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23266255 | 1.00 | LGALS8 (0.46) | LGALS8LGALS3LGALS4ACHEMAOB | |
| SCHEMBL23266230 | 0.89 | MAOB (0.47) | ACHEMAOBSLC5A1SLC5A2 | |
| SCHEMBL23266182 | 0.89 | MAOB (0.47) | ACHEMAOBSLC5A1SLC5A2 | |
| SCHEMBL23266326 | 0.88 | SLC5A1 (0.56) | MAOBSLC5A1SLC5A2 | |
| SCHEMBL23266192 | 0.88 | SLC5A1 (0.56) | MAOBSLC5A1SLC5A2 | |
| SCHEMBL23266310 | 0.88 | SLC5A1 (0.56) | MAOBSLC5A1SLC5A2 | |
| SCHEMBL23350452 | 0.88 | SLC5A1 (0.56) | MAOBSLC5A1SLC5A2 | |
| SCHEMBL23266324 | 0.88 | SLC5A1 (0.56) | MAOBSLC5A1SLC5A2 | |
| SCHEMBL23266190 | 0.88 | SLC5A1 (0.56) | MAOBSLC5A1SLC5A2 | |
| SCHEMBL23266188 | 0.88 | SLC5A1 (0.56) | MAOBSLC5A1SLC5A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11325937-B2 | Glycoside compound and preparation method therefor, composition, application, and intermediate | SHANGHAI HUTCHISON PHARMACEUTICALS LIMITED (CN) | 2022-05-10 | — | — | US | disclosed |
| EP-3819303-A1 | GLYCOSIDE COMPOUND AND PREPARATION METHOD THEREFOR, COMPOSITION, APPLICATION, AND INTERMEDIATE | Shanghai Hutchison Pharmaceuticals Limited (CN) | 2021-05-12 | — | — | EP | disclosed |
| US-20210115082-A1 | GLYCOSIDE COMPOUND AND PREPARATION METHOD THEREFOR, COMPOSITION, APPLICATION, AND INTERMEDIATE | SHANGHAI HUTCHISON PHARMACEUTICALS LIMITED (CN) | 2021-04-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11325937-B2 | Glycoside compound and preparation method therefor, composition, application, and intermediate | VEGFA, FLT4, FLT1 | LGALS8 904/4885LGALS3 509/4885LGALS4 1166/4885 |
| US-20210115082-A1 | GLYCOSIDE COMPOUND AND PREPARATION METHOD THEREFOR, COMPOSITION, APPLICATION, AND INTERMEDIATE | VEGFA, FLT4, FLT1 | LGALS8 904/4885LGALS3 509/4885LGALS4 1166/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.